Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. | After ...

BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest ...

Investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) need to pay close attention to the stock based on moves in the options ...

1 Day APLS -4.22% DJIA -0.60% S&P Mid Cap 400 -0.18% Health Care/Life Sciences 0.16% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharmaceuticals (TERN – Research Report) today and set a price ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Beam Therapeutics Inc.’s BEAM share price has surged by 5.12%, which has investors questioning if this is right time to sell.

Story Jan. 13 - Apellis Pharmaceuticals: As it prioritizes commercializing geographic atrophy treatment Syfovre in the U.S., Apellis is cutting about 40 non-U.S. employees. Release Jan 10 ...